An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Spruce Biosciences (NASDAQ: SPRB), a late-stage biopharmaceutical company, announced that CEO Javier Szwarcberg will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET. The company focuses on developing therapies for rare endocrine disorders, particularly its product candidate, tildacerfont, aimed at treating classic congenital adrenal hyperplasia and polycystic ovary syndrome. Interested parties can access the live webcast here and find an archived copy on the investor relations website.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.
Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Spruce is also developing tildacerfont for women suffering from a rare form of polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
When is Spruce Biosciences presenting at the SVB Securities Global Biopharma Conference?
Spruce Biosciences will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.
Who is presenting for Spruce Biosciences at the conference?
CEO Javier Szwarcberg will present for Spruce Biosciences at the conference.
Where can I watch the Spruce Biosciences presentation?
The presentation can be accessed via a live webcast here.
What is the focus of Spruce Biosciences' research?
Spruce Biosciences focuses on developing novel therapies for rare endocrine disorders, especially classic congenital adrenal hyperplasia and polycystic ovary syndrome.
